Cargando…
Clinicopathological analysis of primary intestinal diffuse large B‐cell lymphoma: Prognostic evaluation of CD5, PD‐L1, and Epstein‐Barr virus on tumor cells
BACKGROUND: Primary intestinal diffuse large B‐cell lymphoma (iDLBCL) is rare. In this study, we investigated the clinicopathological features of this disease to further understand the prognostic value of CD5, programmed cell death ligand 1 (PD‐L1), and Epstein‐Barr virus (EBV) on tumor cells. METHO...
Autores principales: | Ishikawa, Eri, Kato, Seiichi, Shimada, Kazuyuki, Tanaka, Tsutomu, Suzuki, Yuka, Satou, Akira, Kohno, Kei, Sakakibara, Ayako, Yamamura, Takeshi, Nakamura, Masanao, Miyahara, Ryoji, Goto, Hidemi, Nakamura, Shigeo, Hirooka, Yoshiki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6308116/ https://www.ncbi.nlm.nih.gov/pubmed/30449068 http://dx.doi.org/10.1002/cam4.1875 |
Ejemplares similares
-
A prognostic model, including the EBV status of tumor cells, for primary gastric diffuse large B‐cell lymphoma in the rituximab era
por: Ishikawa, Eri, et al.
Publicado: (2018) -
Reappraisal of nodal Epstein‐Barr Virus‐negative cytotoxic T‐cell lymphoma: Identification of indolent CD5(+) diseases
por: Yamashita, Daisuke, et al.
Publicado: (2018) -
Epstein-Barr Virus Positive B-Cell Lymphoproliferative Disorder of the Gastrointestinal Tract
por: Ishikawa, Eri, et al.
Publicado: (2021) -
PD‐L1 expression on tumor or stromal cells of nodal cytotoxic T‐cell lymphoma: A clinicopathological study of 50 cases
por: Yamashita, Daisuke, et al.
Publicado: (2020) -
PD‐L1 (SP142) expression in neoplastic cells predicts a poor prognosis for patients with intravascular large B‐cell lymphoma treated with rituximab‐based multi‐agent chemotherapy
por: Suzuki, Yuka, et al.
Publicado: (2020)